Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 20241  TRELEGY net sales of $854M, as reported by GSK, increased 14% versus Q1 20242 CYPRESS study open label enrollment nearing completion with final patient expected to be enrolled by late summer Quarter-end cash balance of $131 million, with no debt Reaffirming all financial guidance metricsDUBLIN, May 8, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) ...